Pharmaceutical companies, which develop both over-the-counter and prescription drugs, have been among the biggest political spenders for years. While the industry has traditionally supported Republican candidates, some key players have recently increased donations to Democratic candidates as the GOP’s power in Washington erodes.
The pharmaceutical manufacturing industry will likely fair better this decade now that President Barack Obama’s initial plan to institute a public health insurance did not become a part of sweeping health care reform legislation signed into law in 2010. A government-run plan, because of its size, would have had considerable negotiating power to draw down drug prices. [Read more Background]
Top Contributors, 2011-2012
Contributor Amount Pfizer Inc $702,391 Amgen Inc $574,648 AstraZeneca PLC $527,501 Abbott Laboratories $406,773 Merck & Co $363,041 GlaxoSmithKline $325,741 Eli Lilly & Co $264,762 Novartis AG $205,209 Bayer Corp $124,650 Endo Pharmaceuticals $116,400 Perrigo Co $111,475 Mutual Pharmaceutical $105,000 Allergan Inc $88,000 Teva Pharmaceuticals USA $86,870 Sanofi-Aventis $78,300 Bristol-Myers Squibb $70,050 Pharmaceutical Rsrch & Mfrs of America $65,450 Nostrum Pharmaceuticals $62,300 Cephalon Inc $61,250 Takeda Pharmaceuticals North America $61,250
Contribution Trends, 1990-2010
Lobbying Totals, 1998-2010
Top Recipients, 2011-2012
Candidate Office Amount Obama, Barack (D) $129,139 Romney, Mitt (R) $89,300 Upton, Fred (R-MI) House $77,575 Brown, Scott P (R-MA) Senate $76,483 Hatch, Orrin G (R-UT) Senate $69,400
Data for the current election cycle were released by the Federal Election Commission on Monday, February 13, 2012
Feel free to distribute or cite this material, but please credit the Center for Responsive Politics.
Saturday, March 10, 2012
Lobbying by Pharmaceutical Manufacturing | OpenSecrets